Antiplatelet Therapy in Patients with Acute Coronary Syndrome: An Update

Authors

  • Adnan Bashar Department of Cardiology, Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka
  • Md Harisul Hoque Department of Cardiology, Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka
  • MSI Tipu Chowdhury Department of Cardiology, Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka
  • ATM Iqbal Hasan Department of Cardiology, Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka
  • Khurshed Ahmed Department of Cardiology, Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka

DOI:

https://doi.org/10.3329/uhj.v17i1.50884

Keywords:

Antiplatelet Therapy, Coronary Syndrome

Abstract

Antiplatelet therapy is the cornerstone in the treatment of acute coronary syndrome. Aspirin is the most widely used antiplatelet agent followed by P2Y12 inhibitors. Glycoprotein (GP) IIb-IIIa antagonists are also gaining popularity as an antiplatelet agents during peri-PCI period. This review article summarizes the indications, duration of dual antiplatelet therapy (DAPT) in ACS setting. Antiplatelet therapy in special situations like atrial fibrillation and thrombocytopenia are discussed here. Issues like switching between P2Y12 inhibitors and genetic testing of antiplatelet agents are also mentioned in this article

University Heart Journal Vol. 17, No. 1, Jan 2021; 66-70

Downloads

Download data is not yet available.
Abstract
346
PDF
382

Downloads

Published

2020-12-21

How to Cite

Bashar, A., Hoque, M. H., Chowdhury, M. T., Hasan, A. I., & Ahmed, K. (2020). Antiplatelet Therapy in Patients with Acute Coronary Syndrome: An Update. University Heart Journal, 17(1), 66–70. https://doi.org/10.3329/uhj.v17i1.50884

Issue

Vol. 17 No. 1 (2021)

Section

Review Articles

License

Authors are required to transfer their copyright to the University Heart Journal.